Carvedilol compared with Metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure

Background—β-Blockers exert a prognostic benefit in the treatment of chronic heart failure. Their pharmacological properties vary. The only substantial comparative trial to date—the Carvedilol or Metoprolol European Trial—has compared carvedilol with short-acting metoprolol tartrate at different dos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fröhlich, Hanna (VerfasserIn) , Zhao, Jingting Désirée (VerfasserIn) , Täger, Tobias (VerfasserIn) , Cebola, Rita (VerfasserIn) , Schellberg, Dieter (VerfasserIn) , Katus, Hugo (VerfasserIn) , Frankenstein, Lutz (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 14 Jul 2015
In: Circulation. Heart failure
Year: 2015, Jahrgang: 8, Heft: 5, Pages: 887-896
ISSN:1941-3297
DOI:10.1161/CIRCHEARTFAILURE.114.001701
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/CIRCHEARTFAILURE.114.001701
Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.114.001701
Volltext
Verfasserangaben:Hanna Fröhlich, MD, Jingting Zhao, Tobias Täger, MD, Rita Cebola, MD, Dieter Schellberg, PhD, Hugo A. Katus, MD, PhD, Morten Grundtvig, MD, PhD, Torstein Hole, MD, PhD, Dan Atar, MD, PhD, Stefan Agewall, MD, PhD, Lutz Frankenstein, MD

MARC

LEADER 00000caa a2200000 c 4500
001 1724720899
003 DE-627
005 20230427070033.0
007 cr uuu---uuuuu
008 200714s2015 xx |||||o 00| ||eng c
024 7 |a 10.1161/CIRCHEARTFAILURE.114.001701  |2 doi 
035 |a (DE-627)1724720899 
035 |a (DE-599)KXP1724720899 
035 |a (OCoLC)1341345470 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fröhlich, Hanna  |d 1985-  |e VerfasserIn  |0 (DE-588)1014274141  |0 (DE-627)705202550  |0 (DE-576)348549091  |4 aut 
245 1 0 |a Carvedilol compared with Metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure  |c Hanna Fröhlich, MD, Jingting Zhao, Tobias Täger, MD, Rita Cebola, MD, Dieter Schellberg, PhD, Hugo A. Katus, MD, PhD, Morten Grundtvig, MD, PhD, Torstein Hole, MD, PhD, Dan Atar, MD, PhD, Stefan Agewall, MD, PhD, Lutz Frankenstein, MD 
264 1 |c 14 Jul 2015 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.07.2020 
520 |a Background—β-Blockers exert a prognostic benefit in the treatment of chronic heart failure. Their pharmacological properties vary. The only substantial comparative trial to date—the Carvedilol or Metoprolol European Trial—has compared carvedilol with short-acting metoprolol tartrate at different dose equivalents. We therefore addressed the relative efficacy of equal doses of carvedilol and metoprolol succinate on survival in multicenter hospital outpatients with chronic heart failure.Methods and Results—Four thousand sixteen patients with stable systolic chronic heart failure who were using either carvedilol or metoprolol succinate were identified in the Norwegian Heart Failure Registry and The Heart Failure Registry of the University of Heidelberg, Germany. Patients were individually matched on both the dose equivalents and the respective propensity scores for β-blocker treatment. During a follow-up for 17 672 patient-years, it was found that 304 (27.2%) patients died in the carvedilol group and 1066 (36.8%) in the metoprolol group. In a univariable analysis of the general sample, metoprolol therapy was associated with higher mortality compared with carvedilol therapy (hazard ratio, 1.49; 95% confidence interval, 1.31-1.69; P<0.001). This difference was not seen after multivariable adjustment (hazard ratio, 0.93; 95% confidence interval, 0.57-1.50; P=0.75) and adjustment for propensity score and dose equivalents (hazard ratio, 1.06; 95% confidence interval, 0.94-1.20; P=0.36) or in the propensity and dose equivalent-matched sample (hazard ratio, 1.00; 95% confidence interval, 0.82-1.23; P=0.99). These results were essentially unchanged for all prespecified subgroups.Conclusions—In outpatients with chronic heart failure, no conclusive association between all-cause mortality and treatment with carvedilol or metoprolol succinate was observed after either multivariable adjustment or multilevel propensity score matching. 
700 1 |a Zhao, Jingting Désirée  |d 1991-  |e VerfasserIn  |0 (DE-588)112970923X  |0 (DE-627)884347478  |0 (DE-576)486496031  |4 aut 
700 1 |a Täger, Tobias  |d 1981-  |e VerfasserIn  |0 (DE-588)1026375959  |0 (DE-627)726658243  |0 (DE-576)370501403  |4 aut 
700 1 |a Cebola, Rita  |d 1982-  |e VerfasserIn  |0 (DE-588)1033462306  |0 (DE-627)741271672  |0 (DE-576)38105862X  |4 aut 
700 1 |a Schellberg, Dieter  |e VerfasserIn  |0 (DE-588)1028373023  |0 (DE-627)730619974  |0 (DE-576)375906010  |4 aut 
700 1 |a Katus, Hugo  |d 1951-  |e VerfasserIn  |0 (DE-588)108916618  |0 (DE-627)577155040  |0 (DE-576)289625076  |4 aut 
700 1 |a Frankenstein, Lutz  |d 1973-  |e VerfasserIn  |0 (DE-588)124198937  |0 (DE-627)63440766X  |0 (DE-576)328373281  |4 aut 
773 0 8 |i Enthalten in  |t Circulation. Heart failure  |d Philadelphia, Pa. : Lippincott, Williams & Wilkins, 2008  |g 8(2015), 5, Seite 887-896  |h Online-Ressource  |w (DE-627)567145719  |w (DE-600)2428100-1  |w (DE-576)299311058  |x 1941-3297  |7 nnas  |a Carvedilol compared with Metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure 
773 1 8 |g volume:8  |g year:2015  |g number:5  |g pages:887-896  |g extent:10  |a Carvedilol compared with Metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure 
856 4 0 |u https://doi.org/10.1161/CIRCHEARTFAILURE.114.001701  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.114.001701  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200714 
993 |a Article 
994 |a 2015 
998 |g 124198937  |a Frankenstein, Lutz  |m 124198937:Frankenstein, Lutz  |d 910000  |d 910100  |d 50000  |e 910000PF124198937  |e 910100PF124198937  |e 50000PF124198937  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 11  |y j 
998 |g 108916618  |a Katus, Hugo  |m 108916618:Katus, Hugo  |d 910000  |d 910100  |e 910000PK108916618  |e 910100PK108916618  |k 0/910000/  |k 1/910000/910100/  |p 6 
998 |g 1028373023  |a Schellberg, Dieter  |m 1028373023:Schellberg, Dieter  |d 910000  |d 910100  |e 910000PS1028373023  |e 910100PS1028373023  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 1033462306  |a Cebola, Rita  |m 1033462306:Cebola, Rita  |d 910000  |d 910100  |e 910000PC1033462306  |e 910100PC1033462306  |k 0/910000/  |k 1/910000/910100/  |p 4 
998 |g 1026375959  |a Täger, Tobias  |m 1026375959:Täger, Tobias  |d 910000  |d 910100  |e 910000PT1026375959  |e 910100PT1026375959  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 112970923X  |a Zhao, Jingting Désirée  |m 112970923X:Zhao, Jingting Désirée  |d 50000  |e 50000PZ112970923X  |k 0/50000/  |p 2 
998 |g 1014274141  |a Fröhlich, Hanna  |m 1014274141:Fröhlich, Hanna  |d 910000  |d 910100  |e 910000PF1014274141  |e 910100PF1014274141  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1724720899  |e 3724259131 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Gesehen am 14.07.2020"],"person":[{"display":"Fröhlich, Hanna","given":"Hanna","role":"aut","family":"Fröhlich"},{"given":"Jingting Désirée","display":"Zhao, Jingting Désirée","role":"aut","family":"Zhao"},{"family":"Täger","role":"aut","given":"Tobias","display":"Täger, Tobias"},{"given":"Rita","display":"Cebola, Rita","role":"aut","family":"Cebola"},{"family":"Schellberg","role":"aut","given":"Dieter","display":"Schellberg, Dieter"},{"display":"Katus, Hugo","given":"Hugo","family":"Katus","role":"aut"},{"role":"aut","family":"Frankenstein","display":"Frankenstein, Lutz","given":"Lutz"}],"recId":"1724720899","name":{"displayForm":["Hanna Fröhlich, MD, Jingting Zhao, Tobias Täger, MD, Rita Cebola, MD, Dieter Schellberg, PhD, Hugo A. Katus, MD, PhD, Morten Grundtvig, MD, PhD, Torstein Hole, MD, PhD, Dan Atar, MD, PhD, Stefan Agewall, MD, PhD, Lutz Frankenstein, MD"]},"language":["eng"],"origin":[{"dateIssuedDisp":"14 Jul 2015","dateIssuedKey":"2015"}],"relHost":[{"recId":"567145719","origin":[{"publisher":"Lippincott, Williams & Wilkins","dateIssuedDisp":"2008-","dateIssuedKey":"2008","publisherPlace":"Philadelphia, Pa."}],"title":[{"title_sort":"Circulation","partname":"Heart failure","title":"Circulation","subtitle":"an official journal of the American Heart Association"}],"id":{"eki":["567145719"],"issn":["1941-3297"],"zdb":["2428100-1"]},"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2008 -"],"language":["eng"],"part":{"year":"2015","volume":"8","text":"8(2015), 5, Seite 887-896","pages":"887-896","extent":"10","issue":"5"},"titleAlt":[{"title":"Circulation / Heart failure"}],"disp":"Carvedilol compared with Metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failureCirculation. Heart failure","type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"American Heart Association","role":"isb"}]}],"id":{"eki":["1724720899"],"doi":["10.1161/CIRCHEARTFAILURE.114.001701"]},"physDesc":[{"extent":"10 S."}],"title":[{"title":"Carvedilol compared with Metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure","title_sort":"Carvedilol compared with Metoprolol succinate in the treatment and prognosis of patients with stable chronic heart failure"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a FROEHLICHHCARVEDILOL1420